Research Brought to Life

Clinical trials are the most important tool we have for improving the survival of patients with cancer. You should discuss with your doctor whether a clinical trial is available and appropriate for you.

Reset
Reset

IMpress_001

IMpress_001 Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) DiseaseMyelodysplastic Syndromes Acute Myeloid Leukemia SummaryThe purpose of this study is to evaluate the…
Read More

CTX112

CTX112 A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies DiseaseB-cell Lymphoma Non-Hodgkin Lymphoma B-cell Malignancy Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Follicular…
Read More

M20-621

M20-621 A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma…
Read More

MagnetisMM-5

MagnetisMM-5 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/​Refractory Multiple Myeloma (MAGNETISMM-5) DiseaseMultiple Myeloma SummaryBrief Summary: The purpose of…
Read More

PRT2527-02

PRT2527-02 A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies DiseaseAggressive B-Cell Non-Hodgkin’s Lymphoma Aggressive B-Cell NHL Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma (MCL) Richter’s Syndrome SummaryThis…
Read More

DR-01-ONC-001

DR-01-ONC-001 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas DiseaseLGLL – Large Granular Lymphocytic Leukemia Primary Cutaneous T-Cell Lymphoma – Category Primary Cutaneous CD8-Positive…
Read More

LOXO-BTK-20019

LOXO-BTK-20019 Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) DiseaseLymphoma, Mantle-Cell SummaryThis is a Phase 3 global, randomized, open-label study…
Read More

80948543LYM1001

80948543LYM1001 A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) DiseaseLymphoma, Non-Hodgkin Leukemia, Lymphocytic,…
Read More

BGB-11417-103

BGB-11417-103 A Study of BGB-11417 in Participants With Myeloid Malignancies DiseaseAcute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm SummaryThe study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and…
Read More

M20-638

M20-638 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) DiseaseFollicular Lymphoma SummaryFollicular…
Read More

MajesTEC-9

MajesTEC-9 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) DiseaseRelapsed or Refractory Multiple Myeloma SummaryThe…
Read More

SLN124-004

SLN124-004 Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera DiseasePolycythemia Vera SummaryThis is a Phase 1/2,…
Read More

MAJIC

MAJIC A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma DiseaseChronic Lymphocytic Leukemia…
Read More

DZ2022B0002

DZ2022B0002 A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) DiseaseNon-Hodgkin Lymphoma…
Read More

AMLM26/T5 INTERCEPT

AMLM26/T5 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – MBG453 OR MBG453 and Azacitidine DiseaseLeukaemia…
Read More

BLOCK PCNSL (NHL32)

BLOCK PCNSL (NHL32) An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma DiseaseLymphoma (non Hodgkin’s lymphoma) SummaryThe purpose of this study is…
Read More

SUCCESSOR-1 (CA057-001)

SUCCESSOR-1 (CA057-001) A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma…
Read More

ASTX660-03

ASTX660-03 A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) DiseaseRelapsed/Refractory Peripheral T-cell Lymphoma SummaryThe primary purpose…
Read More

BELLWAVE

Bellwave (MK-1026-003) A Phase 2 Study to Evaluate the Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies DiseaseHematologic Malignancies SummaryThe purpose of this study is to evaluate…
Read More

NHL35: ALLG-PACIFIC

NHL35: ALLG-PACIFIC An open label phase 2 study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for primary mediastinal B-Cell lymphoma DiseaseB-Cell Lymphoma Summary open label phase II study of R-CHOP…
Read More

Zentalis ZN-d5-003

Zentalis ZN-d5-003 This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis. Disease Amyloidosis AL Amyloidosis SummaryA Single…
Read More

SNDX-5613-0700

SNDX-5613-0700 A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Disease Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Mixed Lineage Acute Leukemia…
Read More

EZH-302

EZH-302 A Phase 1b/3 Double Blind Randomized, Active-Controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma DiseaseRelapsed/Refractory Follicular…
Read More

ESCALADE

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)
Read More

LOXO-BTK-20022

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously…
Read More

BGB-16673-101

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients…
Read More

CRSP-ONC-001

This is an open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX110 in subjects…
Read More

Epcoritamab

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in…
Read More

AMLM25

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly Acute…
Read More

75348780LYM1001

A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in…
Read More

AMLM22/D2

The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to…
Read More

GCT-3013-01

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Read More

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature…
Read More

Clinical Trial FAQ’s